- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02581696
The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
February 3, 2017 updated by: Boryung Pharmaceutical Co., Ltd
An Open-label, Multiple-dose, Single-arm, Phase 1 Study to Evaluate the Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers.
Subjects judged to be appropriate to this study by screening before 28days of first administration.
Subjects administrate Lafutidine bid during period I.
After wash-out period, administrate Irsogladine maleate qd during Period II.
After than, coadministration Lafutidine bid and Irsogladine maleate qd.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- The Catholic University of Korea, Seoul St.Mary's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy subjects between the ages of 19 and 50 at the screening
Male subjects whose weight is greater than 55kg Female subjects whose weight is greater than 50kg and within ±20% range of ideal body weight.
Ideal body weight(kg) = (Height(cm) - 100) * 0.9
For female subjects must show negative for urine pregnancy test and also must meet one of the below listed criteria:
- A menopausal woman (Menstruation should stop at least 2 years ago)
- Take sterilization operation (Hysterectomy, Ovariotomy, Tubal ligation, any other operation)
- Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subject.
- Before 3 months of the screening and 1month after the end of drug administration, subjects must meet contraception requirements.
- For avoiding the drug-drug interaction, subjects must not use any contraceptive drugs and must choose abstinence or use physical block.
- A sexually active male subjects must use and accepted method of contraception during the course of the clinical study and must not donate sperms until a month after finishing drug administration. (If male subjects oneself or female partner is sterility, that does not apply.)
- Subjects who understand the clinical study completely, agree to participate and sign written consent form for conduct precautions
Exclusion Criteria:
- Subjects having liver system disorders, kidney disorders, digestive system disorders, cardiovascular disorders, respiratory disorders, endocrine disorders, neurological disorder or hematological disorders, psychiatric disorders, or a history of malignancy, disorders
- Subjects having a history of gastrointestinal system disorders influencing drug absorption(i.e, Crohn's disease, ulcer) or surgery (except simple typhlectomy or hernia repair surgery)
- Subjects having a history of hypersensitivity to additional ingredient or clinically significant hypersensitivity to lafutidine and Irsogladine or any other drug.
- Subjects who judged for inappropriate to physical examination. ( Disease history, physical examine, vital sign, EKG examine, laboratory examine and so on ).
- Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption and any other hereditary disorder.
- Subjects who is sitting after 5minutes break, having Systolic blood pressure ≥ 140 mmHg and Diastolic blood pressure ≤ 90 mmHg, or Systolic blood pressure ≥ 90 mmHg and Diastolic blood pressure ≤ 60 mmHg on vital sign
- Subjects having a history of drug abuse or positive drug abuse urinalysis testing at screening.
- Subjects who is pregnancy or feed breast milk.
- Subjects who has participated in another clinical study before study drug administration Subjects having blood donation within two months or component blood donation within one month before study drug administration
- Subjects who has drunken beverages caffeine-containing or alcohol or smoking during prohibition period
- Subjects who has judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm
This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers.
Subjects judged to be appropriate to this study by screening.
|
Lafutidine 10mg, 1 tablet, bid
Other Names:
Irsogladine maleate 2mg, 2 tablet, qd
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration versus time curve of Lafutidine and Irsogladine maleate
Time Frame: Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times)
|
Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak Plasma Concentration of Lafutidine and Irsogladine
Time Frame: Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times)
|
Sampling time 1, 19, 21days before drug administration, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24hr after drug administration. (total 24times)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Seoung-hun Han, Professor, The Catholic University of Korea
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
October 12, 2015
First Submitted That Met QC Criteria
October 20, 2015
First Posted (Estimate)
October 21, 2015
Study Record Updates
Last Update Posted (Estimate)
February 6, 2017
Last Update Submitted That Met QC Criteria
February 3, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Duodenal Diseases
- Peptic Ulcer
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Gastrointestinal Agents
- Protective Agents
- Anti-Ulcer Agents
- Histamine Antagonists
- Histamine Agents
- Anticarcinogenic Agents
- Radiation-Protective Agents
- Histamine H2 Antagonists
- Lafutidine
- Irsogladine
Other Study ID Numbers
- BR-LAF-CT-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peptic Ulcer
-
Uayporn KaosombatwattanaCompleted
-
South Valley UniversityCompleted
-
Erasme University HospitalGastrostartCompletedPerforated Peptic UlcerNetherlands
-
Kaohsiung Veterans General Hospital.Completed
-
AstraZenecaCompleted
-
Chinese University of Hong KongNational Taiwan University Hospital; Okayama University; Tokyo University; Tsuyama... and other collaboratorsCompletedBleeding Peptic UlcerChina
-
Azienda USL ModenaRecruiting
-
Kyunghee University Medical CenterCompletedActive Peptic Ulcer Disease/GI BleedingKorea, Republic of
-
Assiut UniversityNot yet recruitingPerforated Peptic Ulcer
Clinical Trials on Lafutidine
-
Wuhan Union Hospital, ChinaCompleted
-
Taiho Pharmaceutical Co., Ltd.UCB PharmaCompletedGastroesophageal RefluxJapan
-
Boryung Pharmaceutical Co., LtdCompleted
-
King Saud UniversityCompletedPulmonary Aspiration of Gastric Contents
-
Boryung Pharmaceutical Co., LtdCompletedGastric UlcerKorea, Republic of
-
Canadian Network for Observational Drug Effect...Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...CompletedGastroesophageal Reflux Disease (GERD) | Community-acquired PneumoniaCanada